A Randomized, Multiple Dose, Placebo and Active Controlled 3-Way Crossover Study to Investigate the Effects of Esreboxetine on QTc Interval in Healthy Volunteers.
Phase of Trial: Phase I
Latest Information Update: 09 Dec 2009
At a glance
- Drugs Esreboxetine; Moxifloxacin
- Indications Fibromyalgia
- Focus Pharmacodynamics
- Sponsors Pfizer
- 09 Dec 2009 Status changed from discontinued to completed as reported by ClinicalTrials.gov.
- 25 Feb 2009 Status changed from recruiting to discontinued. Pfizer has decided to discontinue development of this drug, as reported in a media release.
- 24 Dec 2008 New trial record.